Form 4: Abeona Therapeutics Director Donald A. Wuchterl Acquires Shares
SEC Form 4 Filing
Director Donald A. Wuchterl reports acquisition of Abeona Therapeutics shares.
Summary
- On July 8, 2024, Donald A. Wuchterl, a director of Abeona Therapeutics Inc., acquired 23,611 shares of common stock.
- The shares were acquired at a price of $0.00.
- Following the transaction, Wuchterl directly owns 102,714 shares of Abeona Therapeutics Inc.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock acquisition by a director. The acquisition itself could be interpreted as mildly positive, but the filing is simply a procedural requirement.
Positives
- A director's acquisition of shares could be seen as a positive signal, indicating confidence in the company's future prospects.
Future Outlook
The restricted stock acquired will vest on July 8, 2025.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of shares by a director may positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 07/08/2024 | Date of transaction: Acquisition of shares. |
| 07/08/2025 | Vesting date for restricted stock. |
| 07/09/2024 | Date of signature on the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.